The only thing that Tony Blinken might have going for him is that he plays guitar. He was ineffectual and lacking in gravitas in dealing with America’s friends and enemies. He was the driving force ...
A judge will decide whether Timothy Farquer, 53, is guilty or not. The bench trial is set for July 29-31. A final pretrial is set for July 6. The Iowa City Police Department is investigating a ...
The president's youngest son has "inherited his father’s interest in making money and a name for himself," a source tells PEOPLE Linda Marx is a writer and reporter for PEOPLE in the areas of ...
Sources close to the family tell PEOPLE that Barron has "inherited his father’s interest in making money and a name for himself," with one notable difference The youngest Trump is already estimated to ...
The president's youngest son has "inherited his father’s interest in making money and a name for himself," a source tells PEOPLE 'This is the last warning.' Iran threatens US warships after they throw ...
Barron Trump turns 20 years old on Friday, March 20, and sources close to President Donald Trump's youngest son tell PEOPLE how he's preparing for his "next phase" of life — which may involve treading ...
Why is Christian Science in our name? Our name is about honesty. The Monitor is owned by The First Church of Christ, Scientist, and we’ve always been transparent about that. The church publishes the ...
Let’s go down the list. Nebraska: 83-80 loss. Michigan State: 85-80 overtime loss. Wisconsin; 92-90 overtime loss. UCLA: 95-94 overtime loss. Wisconsin again: 91-88 overtime loss. That is every single ...
CLEVELAND — When a Tornado Watch or a Tornado Warning is issued in your area, you might be wondering what each specific weather alert actually means... So what's the difference between a Tornado Watch ...
The new MacBook Neo is officially here, and it gives MacBook Air a run for its money when it comes to casual usage. So what exactly is the $500 difference between Apple’s two 13-inch laptops? Let’s ...
The San Diego-based biotech firm Gossamer Bio announced today that it still intends to seek a regulatory path forward with the FDA for its lead drug, seralutinib, despite the treatment narrowly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results